CMS is not collaborating with this effort, even though the FDA removed the indication. Fibrates are inferior and generic, but their priced right...Tier 1.
Zum, Amarin management might be debating themselves whether to move some of their reps in that direction talking to physicians shifting their fibrates patients to V. This may be due to Anchor off label is only for Tg >150 or so. The management might be afraid of targeting those CVD patients who were on add on Fibrates/niacins to statins. We can send them an email asking whether this is what happening.
Market Data 
Markets 
AI
